Psychiatric Medication–Induced Hyperprolactinemia
The Carlat Hospital Psychiatry Report, Volume 2, Number 5&6, July 2022
https://www.thecarlatreport.com/newsletter-issue/chprv2n5-6/
Issue Links: Learning Objectives | Editorial Information
Topics: Antipsychotics | endocrinological side effects | Prolactin
Niki Karavitaki, MD. Senior Clinical Lecturer, Institute of Metabolism and Systems Research, University of Birmingham. Honorary Consultant Endocrinologist, Queen Elizabeth Hospital. Birmingham, UK.
Athanasios Fountas, MD. Clinical Research Fellow, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham. Birmingham, UK.
Dr. Karavitaki has disclosed that she has given webinars for Pfizer on the topic of acromegaly in February 2021 and January 2022. Dr. Hendrick has reviewed the content of this interview and determined that there is no commercial bias as a result of these financial relationships. Dr. Fountas has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Medication–induced hyperprolactinemia is more common than you might think and it can produce detrimental long-term health sequelae. Two endocrinologists — Drs Fountas and Karavitakis – review the work-up and management of this common side effect.
You can't view details of this content, please login or buy subscription here